Clinical Trial Detail

NCT ID NCT03122717
Title Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Gefitinib + Osimertinib

Age Groups: senior adult

No variant requirements are available.